PMID- 33517613
OWN - NLM
STAT- MEDLINE
DCOM- 20211021
LR  - 20211130
IS  - 2233-6087 (Electronic)
IS  - 2233-6079 (Print)
IS  - 2233-6079 (Linking)
VI  - 45
IP  - 5
DP  - 2021 Sep
TI  - Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes 
      Mellitus and Nonalcoholic Fatty Liver Disease.
PG  - 698-707
LID - 10.4093/dmj.2020.0118 [doi]
AB  - BACKGROUND: This study aimed to investigate the association between hepatic 
      steatosis burden and albuminuria in Korean patients with type 2 diabetes mellitus 
      (T2DM) and nonalcoholic fatty liver disease (NAFLD). METHODS: We recruited 100 
      patients with both T2DM and NAFLD, but without chronic kidney disease. 
      Albuminuria was defined as a spot urinary albumin-to-creatinine ratio (ACR) >/=30 
      mg/g. Transient elastography was performed, and the steatosis burden was 
      quantified by controlled attenuation parameter (CAP) with significant steatosis 
      defined as CAP >302 dB/m. RESULTS: The prevalence of significant steatosis and 
      albuminuria was 56.0% and 21.0%, respectively. Subjects with significant 
      steatosis were significantly younger and had a significantly shorter duration of 
      T2DM, greater waist circumference, and higher body mass index, total cholesterol, 
      triglyceride, and low density lipoprotein cholesterol levels, than subjects 
      without severe NAFLD (all P<0.05). Albuminuria was higher in patients with 
      significant steatosis than in patients without significant steatosis (32.1% vs. 
      6.8%, P=0.002). Urinary ACR showed a correlation with CAP (r=0.331, P=0.001), and 
      multiple linear regression analysis revealed a significant association between a 
      high degree of albuminuria and high CAP value (r=0.321, P=0.001). Additionally, 
      multivariate logistic regression analysis demonstrated the independent 
      association between urinary ACR and significant steatosis after adjustment for 
      confounding factors including age, body mass index, duration of T2DM, low density 
      lipoprotein level, and renin-angiotensin system blocker use (odds ratio, 1.88; 
      95% confidence interval, 1.31 to 2.71; P=0.001). CONCLUSION: T2DM patients with 
      NAFLD had a higher prevalence of albuminuria, which correlated with their 
      steatosis burden.
FAU - Han, Eugene
AU  - Han E
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Keimyung University School of Medicine, Daegu, Korea.
FAU - Kim, Mi Kyung
AU  - Kim MK
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Keimyung University School of Medicine, Daegu, Korea.
FAU - Jang, Byoung Kuk
AU  - Jang BK
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Keimyung University School of Medicine, Daegu, Korea.
FAU - Kim, Hye Soon
AU  - Kim HS
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Keimyung University School of Medicine, Daegu, Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210202
PL  - Korea (South)
TA  - Diabetes Metab J
JT  - Diabetes & metabolism journal
JID - 101556588
SB  - IM
CIN - Diabetes Metab J. 2021 Nov;45(6):968-969. PMID: 34847645
CIN - Diabetes Metab J. 2021 Nov;45(6):972-973. PMID: 34847647
MH  - Albuminuria/epidemiology
MH  - Body Mass Index
MH  - *Diabetes Mellitus, Type 2/complications/epidemiology
MH  - *Elasticity Imaging Techniques
MH  - Humans
MH  - *Non-alcoholic Fatty Liver Disease/complications/diagnostic imaging/epidemiology
PMC - PMC8497925
OTO - NOTNLM
OT  - Albuminuria
OT  - Diabetes mellitus, type 2
OT  - Non-alcoholic fatty liver disease
COIS- CONFLICTS OF INTEREST No potential conflict of interest relevant to this article 
      was reported.
EDAT- 2021/02/02 06:00
MHDA- 2021/11/09 06:00
PMCR- 2021/09/01
CRDT- 2021/02/01 02:44
PHST- 2020/05/18 00:00 [received]
PHST- 2020/07/31 00:00 [accepted]
PHST- 2021/02/02 06:00 [pubmed]
PHST- 2021/11/09 06:00 [medline]
PHST- 2021/02/01 02:44 [entrez]
PHST- 2021/09/01 00:00 [pmc-release]
AID - dmj.2020.0118 [pii]
AID - dmj-2020-0118 [pii]
AID - 10.4093/dmj.2020.0118 [doi]
PST - ppublish
SO  - Diabetes Metab J. 2021 Sep;45(5):698-707. doi: 10.4093/dmj.2020.0118. Epub 2021 
      Feb 2.